264 related articles for article (PubMed ID: 16626166)
1. Efficacy of alemtuzumab in organ transplantation: current clinical status.
Ciancio G; Burke GW; Warque ME; Miller J
BioDrugs; 2006; 20(2):85-92. PubMed ID: 16626166
[TBL] [Abstract][Full Text] [Related]
2. Alemtuzumab (Campath-1H): a systematic review in organ transplantation.
Morris PJ; Russell NK
Transplantation; 2006 May; 81(10):1361-7. PubMed ID: 16732169
[TBL] [Abstract][Full Text] [Related]
3. Alemtuzumab in solid organ transplantation and in composite tissue allotransplantation.
Weissenbacher A; Boesmueller C; Brandacher G; Oellinger R; Pratschke J; Schneeberger S
Immunotherapy; 2010 Nov; 2(6):783-90. PubMed ID: 21091110
[TBL] [Abstract][Full Text] [Related]
4. The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation.
Magliocca JF; Knechtle SJ
Transpl Int; 2006 Sep; 19(9):705-14. PubMed ID: 16918530
[TBL] [Abstract][Full Text] [Related]
5. Some observations on prope tolerance.
Calne R; Watson CJ
Curr Opin Organ Transplant; 2011 Aug; 16(4):353-8. PubMed ID: 21666472
[TBL] [Abstract][Full Text] [Related]
6. Emerging role of Alemtuzumab in renal and renal-pancreas transplantation.
Sureshkumar KK; Hussain SM; Zimmer BW; Marcus RJ
Expert Opin Biol Ther; 2008 Oct; 8(10):1605-25. PubMed ID: 18774927
[TBL] [Abstract][Full Text] [Related]
7. Alemtuzumab induction in deceased donor kidney transplantation.
Shin M; Song SH; Kim JM; Kwon CH; Joh JW; Lee SK; Kim SJ
Transplant Proc; 2011; 43(6):2365-78. PubMed ID: 21839271
[TBL] [Abstract][Full Text] [Related]
8. The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation.
Agarwal A; Shen LY; Kirk AD
Transpl Immunol; 2008 Nov; 20(1-2):6-11. PubMed ID: 18824230
[TBL] [Abstract][Full Text] [Related]
9. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
Hale G; Slavin S; Goldman JM; Mackinnon S; Giralt S; Waldmann H
Bone Marrow Transplant; 2002 Dec; 30(12):797-804. PubMed ID: 12476271
[TBL] [Abstract][Full Text] [Related]
10. Alemtuzumab (Campath-1H) induction therapy and dendritic cells: Impact on peripheral dendritic cell repertoire in renal allograft recipients.
Kirsch BM; Haidinger M; Zeyda M; Böhmig GA; Tombinsky J; Mühlbacher F; Watschinger B; Hörl WH; Säemann MD
Transpl Immunol; 2006 Nov; 16(3-4):254-7. PubMed ID: 17138063
[TBL] [Abstract][Full Text] [Related]
11. Alemtuzumab (Campath-1H) in kidney transplantation.
Ciancio G; Burke GW
Am J Transplant; 2008 Jan; 8(1):15-20. PubMed ID: 18093269
[TBL] [Abstract][Full Text] [Related]
12. T-cell depleting antibodies: new hope for induction of allograft tolerance in bone marrow transplantation?
Simpson D
BioDrugs; 2003; 17(3):147-54. PubMed ID: 12749751
[TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation.
Thomas PG; Woodside KJ; Lappin JA; Vaidya S; Rajaraman S; Gugliuzza KK
Transplantation; 2007 Jun; 83(11):1509-12. PubMed ID: 17565326
[TBL] [Abstract][Full Text] [Related]
14. CAMPATH-1 antibodies in stem-cell transplantation.
Hale G; Cobbold S; Novitzky N; Bunjes D; Willemze R; Prentice HG; Milligan D; MacKinnon S; Waldmann H;
Cytotherapy; 2001; 3(3):145-64. PubMed ID: 12171722
[TBL] [Abstract][Full Text] [Related]
15. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H).
Kirk AD; Hale DA; Mannon RB; Kleiner DE; Hoffmann SC; Kampen RL; Cendales LK; Tadaki DK; Harlan DM; Swanson SJ
Transplantation; 2003 Jul; 76(1):120-9. PubMed ID: 12865797
[TBL] [Abstract][Full Text] [Related]
16. Present experience with Campath-1H in organ transplantation and its potential use in pediatric recipients.
Knechtle SJ
Pediatr Transplant; 2004 Apr; 8(2):106-12. PubMed ID: 15049789
[TBL] [Abstract][Full Text] [Related]
17. Alemtuzumab (Millennium/ILEX).
Dumont FJ
Curr Opin Investig Drugs; 2001 Jan; 2(1):139-60. PubMed ID: 11527007
[TBL] [Abstract][Full Text] [Related]
18. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
Hale G; Jacobs P; Wood L; Fibbe WE; Barge R; Novitzky N; Toit C; Abrahams L; Thomas V; Bunjes D; Duncker C; Wiesneth M; Selleslag D; Hidajat M; Starobinski M; Bird P; Waldmann H
Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
[TBL] [Abstract][Full Text] [Related]
19. Alemtuzumab induction in renal transplantation.
Hanaway MJ; Woodle ES; Mulgaonkar S; Peddi VR; Kaufman DB; First MR; Croy R; Holman J;
N Engl J Med; 2011 May; 364(20):1909-19. PubMed ID: 21591943
[TBL] [Abstract][Full Text] [Related]
20. [Monoclonal antibodies in renal transplantation].
Bonvoisin C; Weekers L; Grosch S; Krzesinski JM
Rev Med Liege; 2009; 64(5-6):287-92. PubMed ID: 19642461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]